Syndax Pharmaceuticals, Inc.

NasdaqGS:SNDX Stock Report

Market Cap: US$906.9m

Syndax Pharmaceuticals Valuation

Is SNDX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SNDX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
US$147.89
Fair Value
92.6% undervalued intrinsic discount
11
Number of Analysts

Below Fair Value: SNDX ($10.98) is trading below our estimate of fair value ($147.89)

Significantly Below Fair Value: SNDX is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SNDX?

Key metric: As SNDX is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for SNDX. This is calculated by dividing SNDX's market cap by their current revenue.
What is SNDX's PS Ratio?
PS Ratio21.6x
SalesUS$43.72m
Market CapUS$906.94m

Price to Sales Ratio vs Peers

How does SNDX's PS Ratio compare to its peers?

The above table shows the PS ratio for SNDX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average21.8x
QURE uniQure
39.3x53.79%US$792.2m
VIR Vir Biotechnology
33.6x45.53%US$682.9m
ITOS iTeos Therapeutics
10.9x-91.73%US$383.1m
RGNX REGENXBIO
3.3x21.30%US$443.9m
SNDX Syndax Pharmaceuticals
21.6x38.73%US$906.9m

Price-To-Sales vs Peers: SNDX is good value based on its Price-To-Sales Ratio (21.6x) compared to the peer average (21.8x).

Price to Sales Ratio vs Industry

How does SNDX's PS Ratio compare vs other companies in the US Biotechs Industry?

149 CompaniesPrice / SalesEstimated GrowthMarket Cap
REGN Regeneron Pharmaceuticals
3.7x5.57%US$51.81b
BIIB Biogen
2x-0.63%US$19.02b
INCY Incyte
2.9x2.65%US$12.59b
BMRN BioMarin Pharmaceutical
3.7x7.16%US$11.14b
SNDX 21.6xIndustry Avg. 7.8xNo. of Companies149PS01632486480+
149 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: SNDX is expensive based on its Price-To-Sales Ratio (21.6x) compared to the US Biotechs industry average (7.6x).

Price to Sales Ratio vs Fair Ratio

What is SNDX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SNDX PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio21.6x
Fair PS Ratio0.08x

Price-To-Sales vs Fair Ratio: SNDX is expensive based on its Price-To-Sales Ratio (21.6x) compared to the estimated Fair Price-To-Sales Ratio (0.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SNDX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$10.98
US$34.18
+211.31%
28.82%US$46.00US$17.00n/a11
May ’26US$13.82
US$35.25
+155.07%
29.91%US$51.00US$16.00n/a12
Apr ’26US$12.01
US$36.29
+202.13%
24.44%US$51.00US$16.00n/a14
Mar ’26US$15.64
US$36.23
+131.65%
24.16%US$51.00US$16.00n/a13
Feb ’26US$14.17
US$36.46
+157.32%
23.80%US$51.00US$16.00n/a13
Jan ’26US$13.22
US$36.62
+176.97%
22.74%US$51.00US$18.00n/a13
Dec ’25US$16.72
US$36.69
+119.45%
22.00%US$49.00US$18.00n/a13
Nov ’25US$18.98
US$35.36
+86.29%
15.81%US$45.00US$23.00n/a14
Oct ’25US$19.89
US$35.15
+76.74%
16.24%US$45.00US$23.00n/a13
Sep ’25US$20.55
US$35.15
+71.06%
16.24%US$45.00US$23.00n/a13
Aug ’25US$22.00
US$34.38
+56.29%
16.15%US$45.00US$23.00n/a13
Jul ’25US$21.53
US$34.69
+61.13%
16.16%US$45.00US$23.00n/a13
Jun ’25US$19.27
US$34.17
+77.30%
16.76%US$45.00US$23.00US$10.5412
May ’25US$21.97
US$34.92
+58.93%
17.36%US$45.00US$23.00US$13.8212
Apr ’25US$23.78
US$35.17
+47.88%
17.06%US$45.00US$23.00US$12.0112
Mar ’25US$23.71
US$35.42
+49.37%
16.96%US$45.00US$23.00US$15.6412
Feb ’25US$21.24
US$35.25
+65.96%
16.83%US$45.00US$23.00US$14.1712
Jan ’25US$21.61
US$35.62
+64.81%
13.95%US$45.00US$28.00US$13.2213
Dec ’24US$16.57
US$35.08
+111.73%
12.82%US$43.00US$28.00US$16.7212
Nov ’24US$13.92
US$35.33
+153.83%
12.62%US$43.00US$28.00US$18.9812
Oct ’24US$14.52
US$36.50
+151.38%
7.38%US$42.00US$32.00US$19.8910
Sep ’24US$19.55
US$36.20
+85.17%
7.99%US$42.00US$32.00US$20.5510
Aug ’24US$21.12
US$36.50
+72.82%
7.38%US$42.00US$32.00US$22.0010
Jul ’24US$20.93
US$33.50
+60.06%
6.51%US$37.00US$31.00US$21.538
Jun ’24US$20.17
US$33.78
+67.47%
6.81%US$37.00US$31.00US$19.279
AnalystConsensusTarget
Consensus Narrative from 11 Analysts
US$34.18
Fair Value
67.9% undervalued intrinsic discount
11
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/06/02 08:51
End of Day Share Price 2025/06/02 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Syndax Pharmaceuticals, Inc. is covered by 23 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Peter LawsonBarclays
Jason ZemanskyBofA Global Research
Madhu KumarB. Riley Securities, Inc.